CN104306679A - 治疗流行性脑脊髓膜炎的中药剂及其制备方法 - Google Patents
治疗流行性脑脊髓膜炎的中药剂及其制备方法 Download PDFInfo
- Publication number
- CN104306679A CN104306679A CN201410653814.5A CN201410653814A CN104306679A CN 104306679 A CN104306679 A CN 104306679A CN 201410653814 A CN201410653814 A CN 201410653814A CN 104306679 A CN104306679 A CN 104306679A
- Authority
- CN
- China
- Prior art keywords
- medical material
- chinese medicine
- treatment
- cerebrospinal meningitis
- soak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000009906 Meningitis Diseases 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims description 33
- 238000011282 treatment Methods 0.000 claims abstract description 52
- 239000000463 material Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 57
- 239000012567 medical material Substances 0.000 claims description 42
- 210000000582 semen Anatomy 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 241000466346 Neoalsomitra integrifoliola Species 0.000 claims description 30
- 239000000706 filtrate Substances 0.000 claims description 29
- 239000010231 banlangen Substances 0.000 claims description 24
- 238000005202 decontamination Methods 0.000 claims description 23
- 230000003588 decontaminative effect Effects 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 241000255791 Bombyx Species 0.000 claims description 16
- 239000009636 Huang Qi Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 11
- 238000005325 percolation Methods 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 235000013312 flour Nutrition 0.000 claims description 3
- 238000000703 high-speed centrifugation Methods 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 18
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 7
- 208000026435 phlegm Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 241000255789 Bombyx mori Species 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 240000001829 Catharanthus roseus Species 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract 2
- 230000002588 toxic effect Effects 0.000 abstract 2
- 244000144725 Amygdalus communis Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241001226187 Cyrtomium fortunei Species 0.000 abstract 1
- 244000214240 Galinsoga parviflora Species 0.000 abstract 1
- 235000018914 Galinsoga parviflora Nutrition 0.000 abstract 1
- 241000334160 Isatis Species 0.000 abstract 1
- 241000234435 Lilium Species 0.000 abstract 1
- 241000736251 Magnolia fordiana Species 0.000 abstract 1
- 235000020224 almond Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 15
- 210000004072 lung Anatomy 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- 239000002585 base Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 231100000614 poison Toxicity 0.000 description 9
- 206010011224 Cough Diseases 0.000 description 7
- 206010047700 Vomiting Diseases 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000003440 toxic substance Substances 0.000 description 7
- 230000008673 vomiting Effects 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 206010014080 Ecchymosis Diseases 0.000 description 4
- 206010052369 Encephalitis lethargica Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 201000007227 lymph node tuberculosis Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 201000002498 viral encephalitis Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 201000000297 Erysipelas Diseases 0.000 description 3
- 208000005647 Mumps Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 208000010513 Stupor Diseases 0.000 description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 210000002418 meninge Anatomy 0.000 description 3
- 208000010805 mumps infectious disease Diseases 0.000 description 3
- 210000001989 nasopharynx Anatomy 0.000 description 3
- 206010034754 petechiae Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 229960003048 vinblastine Drugs 0.000 description 3
- 206010010071 Coma Diseases 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 2
- 208000003773 Meningism Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- AUVZFRDLRJQTQF-KXEYLTKFSA-N lochnericine Chemical compound N1C2=CC=CC=C2[C@]2([C@H]34)C1=C(C(=O)OC)C[C@]3(CC)[C@H]1O[C@H]1CN4CC2 AUVZFRDLRJQTQF-KXEYLTKFSA-N 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 210000004916 vomit Anatomy 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000034579 Acute haemorrhagic conjunctivitis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000969468 Athyriaceae Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241001148771 Blechnaceae Species 0.000 description 1
- 241001148764 Blechnopsis orientalis Species 0.000 description 1
- 241000255783 Bombycidae Species 0.000 description 1
- 241000514038 Brainea insignis Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010970 Cor pulmonale chronic Diseases 0.000 description 1
- 241001450685 Corallium japonicum Species 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 244000264242 Descurainia sophia Species 0.000 description 1
- 235000017680 Descurainia sophia Nutrition 0.000 description 1
- 241001148765 Dryopteridaceae Species 0.000 description 1
- 241000393483 Dryopteris crassirhizoma Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000498255 Enterobius vermicularis Species 0.000 description 1
- GNGNFXDVNFGIIL-UHFFFAOYSA-N Ervincinine Natural products CCC12CC(=C3Nc4cc(OC)ccc4C35CCN(CC6OC16)C25)OC(=O)C GNGNFXDVNFGIIL-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- JXLYSJRDGCGARV-PJXZDTQASA-N Leurosidine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-PJXZDTQASA-N 0.000 description 1
- LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 description 1
- 244000210789 Lilium lancifolium Species 0.000 description 1
- 241001359444 Lilium tenuifolium Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- YKTXUUJZENEUGL-MKHRZCKRSA-N Lochnerinine Chemical compound N1C2=CC(OC)=CC=C2[C@]2([C@H]34)C1=C(C(=O)OC)C[C@]3(CC)C1OC1CN4CC2 YKTXUUJZENEUGL-MKHRZCKRSA-N 0.000 description 1
- 241000006404 Lunathyrium Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 241000196123 Matteuccia Species 0.000 description 1
- LELBFTMXCIIKKX-QVRQZEMUSA-N Mitragynine Chemical compound C1=CC(OC)=C2C(CCN3C[C@H]([C@H](C[C@H]33)\C(=C/OC)C(=O)OC)CC)=C3NC2=C1 LELBFTMXCIIKKX-QVRQZEMUSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000196128 Osmundaceae Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- SASWULSUPROHRT-MCIGMTSASA-N Vindorosine Natural products CN([C@H]1[C@](O)([C@@H]2OC(C)=O)C(=O)OC)C3=CC=CC=C3[C@@]11CCN3CC=C[C@]2(CC)[C@@H]13 SASWULSUPROHRT-MCIGMTSASA-N 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- JXLYSJRDGCGARV-KSNABSRWSA-N ac1l29ym Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-KSNABSRWSA-N 0.000 description 1
- -1 acetyl vindorosine Chemical compound 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- AGZMFTKKLPHOMT-DUJTVWLASA-N akuammicine Chemical compound C1CN([C@H]2C3)C\C(=C\C)[C@H]3C(C(=O)OC)=C3[C@@]12C1=CC=CC=C1N3 AGZMFTKKLPHOMT-DUJTVWLASA-N 0.000 description 1
- HKKCLUALMIXSKS-UHFFFAOYSA-N akuammicine Natural products CC=C/1CN2CCC34C2CC1C(=C3Nc5ccccc45)OC(=O)C HKKCLUALMIXSKS-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000026636 chronic pulmonary heart disease Diseases 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000004441 taeniasis Diseases 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗流行性脑脊髓膜炎的中药剂,主要由下列原料药制备而成,均为重量份:贯众0.5-1.2,连翘0.4-1.5,板蓝根0.8-1.6,辣子草0.3-0.8,赛金刚0.6-1.5,长春花0.8-1.6,木莲果0.6-1.0,杏仁1.0-1.8,黄芪1.5-2.0,僵蚕0.3-0.5,葶苈子0.4-1.2,百合0.4-1.0。本发明本具有清热解毒、补气固表、化痰散结功效,经临床应用证实治疗效果好、无毒副作用,能够有效的帮助患者解决疾病困扰。
Description
技术领域
本发明涉及中医中药领域,特别是涉及一种治疗流行性脑脊髓膜炎的中药剂及其制备方法。
背景技术
流行性脑脊髓膜炎简称流脑,是由脑膜炎双球菌引起的化脓性脑膜炎。是一种呼吸道传染病,常发生在冬春剂,以儿童患病较多。致病菌由鼻咽部侵入血循环,形成败血症最后局限于脑膜及脊髓膜,形成化脓性脑脊髓膜病变。病原菌自鼻咽部侵入人体如人体免疫力强,则可迅速将病原菌杀灭,或成为带菌状态;若体内缺乏特异性杀菌抗体或细菌毒力较强时,则病菌可从鼻咽部粘膜进入血液,发展为败血症继而累及脑脊髓膜,形成化脓性脑脊髓脑炎。脑膜炎球菌主要引起隐性感染据统计,60%—70%为无症状带菌者约30%为深呼吸到感染型和出血型,1%为典型流脑病人潜伏期为1-10天,一般为2-3天。流行脑脊髓膜炎分为普通型和爆发型,其中普通型,最常见占全部病例的90%以上。该病以发热、呕吐、头痛颈硬、皮肤癍斑、昏迷惊厥为主要症状。公开号CN 104042937 A(申请号201310079495.7)的中国专利文献公开了一种治疗流行性脑脊髓膜炎的组合物中药,配方由生石膏、龙胆、知母、甘草、白茅根、大青叶等中药组成。公开号CN 103830523 A(申请号201410082018.0)的中国专利文献公开了治疗流行性脑脊髓膜炎的中药剂,由板蓝根10-15g,黄芩3-5g,黄柏3-5g,栀子3-5g,海螺壳10-15g,水蛭1.5-3g,珊瑚9-12g,甘草5-9g,知母10-15克,防风10-15g、牡丹皮10-15克,红参9-12g,当归9-12g,白术9-12g,半夏5-9g,山楂25g,木通25g,升麻25g,朱砂3-5g制备而成。公告号CN 104001108 A(申请号201410213008.6)的中国专利文献公开了治疗流行性脑脊髓膜炎的中药口服液,主要有生石膏30份、犀角10份、黄连5份、生地10份、黄芩10份、葱白15份、玄参9份、郁金10份、西洋参15份、乌梅10份、牡蛎20份、黄柏10份制成。
当代西医对本病的治疗多采用磺胺类药和抗生素类药如青霉素、氯霉素、先锋霉素等,这些药虽见效快,但给患者造成的副反应较大,不是最为理想的治疗手段。目前,中医对于治疗流行性脑脊髓膜炎的配方较少,需要进一步研究开发出疗效稳定,副作用小的组方。
发明内容
针对现有技术的不足,本发明的目的是提供一种制备简单、服用方便的治疗流行性脑脊髓膜炎的中药剂及其制备方法。
本发明的技术方案是:
治疗流行性脑脊髓膜炎的中药剂,主要由下列原料药制备而成,均为重量份:贯众0.5-1.2,连翘0.4-1.5,板蓝根0.8-1.6,辣子草0.3-0.8,赛金刚0.6-1.5,长春花0.8-1.6,木莲果0.6-1.0,杏仁1.0-1.8,黄芪1.5-2.0,僵蚕0.3-0.5,葶苈子0.4-1.2,百合0.4-1.0。
优选的方案中,贯众0.7-1.0,连翘0.9-1.0,板蓝根1.0-1.4,辣子草0.4-0.7,赛金刚0.8-1.3,长春花1.0-1.4,木莲果0.7-0.9,杏仁1.2-1.6,黄芪1.6-1.9,僵蚕0.35-0.45,葶苈子0.6-1.0,百合0.6-0.8。
更加优选的,贯众0.85,连翘0.95,板蓝根1.2,辣子草0.55,赛金刚1.05,长春花1.2,木莲果0.8,杏仁1.4,黄芪1.75,僵蚕0.4,葶苈子0.8,百合0.7。
所述的治疗流行性脑脊髓膜炎的中药制剂,将其制成药学上可接受的汤剂,所述汤剂的制备方法是:
(1)将连翘、板蓝根和木莲果去杂质粉碎,用药材重量3倍的80%的乙醇浸泡,然后渗漉,收集渗漉液;
(2)将赛金刚用清水浸润,切片,然后置于锅中炒至黑色为度,喷洒清水,放凉;
(3)将剩余药材去杂质,洗净,和步骤(2)所制得药材一起粗粉,然后置于砂锅中,浸泡60-90分钟(优选的,浸泡70-80分钟,更加优选的,浸泡75分钟),大火煮开,转小火煎50-80分钟(优选的,转小火煎60-70分钟,更加优选的,转小火煎65分钟),然后趁热过200目筛,收集滤液;
(4)将步骤(1)(3)所得渗漉液和滤液合并,混匀,加热浓缩至原来体积的三分之一,灭菌,分装,即得汤剂。
所述的治疗流行性脑脊髓膜炎的中药制剂汤剂,步骤(1)渗漉所用80%乙醇量为药材重量的4-7倍(优选的,为药材重量的5-6倍,更加优选的,为药材重量的5.5倍)。
所述胶囊剂的制备方法是:
(1)将贯众、板蓝根、僵蚕和百合去杂质,洗净,干燥,粉碎过120-180目筛(优选的,粉碎过140-160目筛,更加优选的,粉碎过150目筛);
(2)将赛金刚用清水浸润,切片,然后置于锅中炒至黑色为度,喷洒清水,放凉;
(3)将剩余药材去杂质后,和步骤(2)所制药材一起浸泡于砂锅中40分钟,然后大火煮开后,转至小火煎30-60分钟(优选的,转至小火煎40-50分钟,更加优选的,转至小火煎45分钟),高速离心过滤,得滤液;
(4)将步骤(3)所得滤液,减压浓缩至相对密度1.24-1.30(优选的,1.27)(50℃)的清膏,加入步骤(1)所制细粉,混合均匀制粒,干燥,分筛,装入胶囊内,即得胶囊剂。
所述的治疗流行性脑脊髓膜炎的中药制剂胶囊剂,步骤(3)浸泡所用水刚好没过药材3cm。
所述稠膏剂的制备方法是:
(1)将赛金刚用清水浸润,切片,然后置于锅中炒至黑色为度,喷洒清水,放凉;
(2)取其他药材去杂质,洗净,与赛金刚一起置于砂锅中浸泡 60分钟,然后密闭大火煮20分钟,过滤,收集滤液,滤渣兑水再次煎煮20分钟,过滤,合并两次滤液;
(3)将步骤(2)所得滤液加热浓缩至约200ml,加入面粉,不断搅拌,熬成稠膏状,即得稠膏剂。
所述的治疗流行性脑脊髓膜炎的中药制剂稠膏剂,步骤(2)滤渣兑水量为刚好没过药材2cm。
所述散剂的制备方法是:
(1)将连翘、板蓝根和木莲果去杂质粉碎,用药材质量4倍的80%的乙醇浸泡,渗漉,收集渗漉液,残渣备用;
(2)将赛金刚用清水浸润,切片,然后置于锅中炒至黑色为度,喷洒清水,放凉;
(3)将剩余药材去杂质,洗净,和步骤(2)所制得药材一起粗粉,然后置于砂锅中,浸泡60-90分钟(优选的,浸泡70-80分钟,更加优选的,浸泡75分钟),大火煮开,转小火煎50-80分钟(优选的,转小火煎60-70分钟,更加优选的,转小火煎65分钟),然后趁热过200目筛,收集滤液;
(4)将步骤(1)(3)所得渗漉液和滤液合并,混匀,真空浓缩至稠膏,再喷雾干燥,粉碎过筛,灭菌,分装,即得散剂。
所述的治疗流行性脑脊髓膜炎的中药制剂散剂,步骤(4)粉碎过300-400目筛(优选的,粉碎过340目筛)。
本发明所用主要中药原料的药理如下:
贯众:基原:为鳞毛蕨科植物粗茎鳞毛蕨,蹄盖蕨科植物蛾眉蕨,球子蕨科植物荚果蕨,紫萁科植物紫萁,乌毛蕨科植物乌毛蕨、苏铁蕨、狗脊蕨等的根茎。性味:苦,凉。归经:入肝、胃经。功能主治:杀蛔、绦、蛲虫,清热,解毒,凉血,止血。治风热感冒。温热斑疹,吐血,衄血,肠风便血,血痢,血崩,带下,疮疡,尿血,月经过多,刀伤出血,蛔虫、饶虫、绦虫病,人工流产,产后出血。
连翘:基原:为木犀科植物连翘的果实。性味:苦,微寒。归经:归肺、心、小肠经。功能主治:清热解毒,消肿散结,疏散风热。用于痈疽,瘰疬,乳痈,丹毒,风热感冒,温病初起,温热人营,高热烦渴,神昏发斑,热淋涩痛。
板蓝根:性味:味苦,性寒。归经:归心经;胃经。功效:清热,解毒,凉血,利咽。主治:治流感,流脑,乙脑,肺炎,丹毒,热毒发斑,神昏吐衄,咽肿,痄腮,火眼,疮疹,舌绛紫暗,喉痹,烂喉丹痧,大头瘟疫,痈肿;可防治流行性乙型脑炎、急慢性肝炎、流行性腮腺炎、骨髓炎。
辣子草:基原:为菊科植物辣子草的全草。性味:淡,平。功能主治:止血,消炎。主治扁桃体炎,咽喉炎,急性黄疸型肝炎;外用治创伤出血。
赛金刚:基原:葫芦科植物赛金刚的块根。性味:味苦;涩;性寒。功能主治:清热解毒;止痛。主菌痢;肠炎;胃炎;咽喉炎;腮腺炎;牙周炎;暴发火眼;扁桃体炎;高热;尿路感染。
杏仁:性味:苦,微温;有小毒。归经:肺经。功能主治:有滋润肺燥,止咳平喘,润肠通便的功效。主治虚劳咳嗽、气喘,胸腹逆闷;肠燥便秘,大便干结。
黄芪:基原:豆科植物蒙古黄芪或膜荚黄芪的干燥根。性味:甘,温。归经:肺经、脾经。功效:补气固表,利尿消肿,托毒排脓,敛疮生肌。主治:用于气虚乏力,食少便溏,中气下陷,久泻脱肛,便血崩漏,表虚自汗,气虚水肿,痈疽难溃,久溃不敛,血虚痿黄,内热消渴;慢性肾炎蛋白尿,糖尿病。
僵蚕:基原:为蚕蛾科昆虫家蚕蛾的幼虫感染白僵菌而僵死的干燥全虫。性味:辛咸,平。归经:入肝经、肺经、胃经。功效:祛风解痉,化痰散结。 主治:中风失音、中风口嘴眼斜、惊痫抽搐、头风、喉风、咽喉肿痛、瘰疬、痄腮、风疹、疮毒喉痹、瘰疬结核、风疮瘾疹、丹毒、乳腺炎。
长春花:基原:为夹竹桃科长春花属植物长春花,黄长春花的全草。成分:长春花中含有吲哚类生物碱70余种,包含长春碱、长春新碱、洛柯定碱、洛柯辛碱、去乙酰文朵尼定碱、长春花碱、长春尼定、洛柯宁碱等。根含生物碱,包括帽柱木碱、阿枯米辛碱、长春西定、洛柯文碱、硫酸卡文辛碱、硫酸留绕西文碱,阿模楷灵碱、硫酸派绕生等。药理:1.抗肿瘤作用 长春花含有的长春碱、长春新碱、环氧长春碱、异长春碱具有明显的抗肿瘤作用。2.抗肿瘤作用机理 长春花抗肿瘤作用与药物对微管蛋白结合的高亲和力直接有关,抑制核酸合成是它的另一机制。3.降血压与扩血管作用 长春花总生物碱不论灌胃、肌注或静注对麻醉犬均有降压作用,还有扩张冠状血管的作用。4.降血糖和降血脂作用 本品叶的水提取物对正常或四氧嘧啶糖尿病兔和犬有降低血糖作用。性味:苦,寒,有毒。功用主治:解毒抗癌,清热平肝。主治多种癌肿,高血压病,痈肿疮毒,烫伤。
木莲果:基原:为木兰科木莲属植物木莲的果实。成分:主要有棕榈酸,油酸,亚油酸。药性:1、《天目山药用植物志》:“具有芳气,味淡。” 2、《全国中草药汇编》:“止咳,通便。”功用主治:通便,止咳。主治实热便秘,老人咳嗽。
葶苈子:基原:为十字花科植物葶苈、琴叶葶苈和播娘蒿的种子。性味:辛;苦;寒。归经:肺经;心经;肝经;胃经;膀胱经。功效:泻肺降气;祛痰平喘;利水消肿;泄逐邪。主治:痰涎壅肺之喘咳痰多;肺痈;水肿;胸腹积水;小便不利;慢性肺源性心脏病;心力衰竭之喘肿;瘰疬结核。
百合:基原:为百合科植物卷丹、百合或细叶百合的干燥肉质鳞叶。性味:甘;微苦;微寒。归经:心经;肺经。功效:养阴润肺;清心安神。主治:阴虚久嗽;痰中带血;热病后期;余热未清,或情志不遂所致的虚烦惊悸、失眠多梦、精神恍惚;痈肿;湿疮。
本发明提供的治疗流行性脑脊髓膜炎的中药剂具有组方科学,制备简单,产品安全等有优点。除此之外,本发明的优良效果还表现在:
1、本发明具有清热解毒、补气固表、化痰散结功效;
2、经临床应用发现,本发明治疗效果好、无毒副作用;
3、本发明所选药材便宜,治疗成本低。
具体实施方式
下面结合实施例和实验例详细说明本发明的技术方案,但保护范围不限于此。
实施例1 治疗流行性脑脊髓膜炎的中药剂,主要由下列原料药制备而成:贯众5g,连翘4g,板蓝根8g,辣子草3g,赛金刚6g,长春花8g,木莲果6g,杏仁10g,黄芪15g,僵蚕3g,葶苈子4g,百合4g。
上述治疗流行性脑脊髓膜炎的中药剂汤剂的制备方法是:
(1)将连翘、板蓝根和木莲果去杂质粉碎,用药材重量3倍的80%的乙醇浸泡,然后渗漉(渗漉所用80%乙醇量为药材重量的7倍),收集渗漉液;
(2)将赛金刚用清水浸润,切片,然后置于锅中炒至黑色为度,喷洒清水,放凉;
(3)将剩余药材去杂质,洗净,和步骤(2)所制得药材一起粗粉,然后置于砂锅中,浸泡60分钟,大火煮开,转小火煎80分钟,然后趁热过200目筛,收集滤液;
(4)将步骤(1)(3)所得渗漉液和滤液合并,混匀,加热浓缩至原来体积的三分之一,灭菌,分装,即得汤剂。
本发明汤剂的服用方法:汤剂为15天一个疗程,每天服用两次(温热),每次60m1-80m1。
实施例2 治疗流行性脑脊髓膜炎的中药剂,主要由下列原料药制备而成:贯众12g,连翘15g,板蓝根16g,辣子草8g,赛金刚15g,长春花16g,木莲果10g,杏仁18g,黄芪20g,僵蚕5g,葶苈子12g,百合10。
治疗流行性脑脊髓膜炎的中药剂胶囊剂的制备方法是:
(1)将贯众、板蓝根、僵蚕和百合去杂质,洗净,干燥,粉碎过150目筛;
(2)将赛金刚用清水浸润,切片,然后置于锅中炒至黑色为度,喷洒清水,放凉;
(3)将剩余药材去杂质后,和步骤(2)所制药材一起浸泡于砂锅中40分钟,浸泡所用水刚好没过药材3cm,然后大火煮开后,转至小火煎45分钟,高速离心过滤,得滤液;
(4)将步骤(3)所得滤液,减压浓缩至相对密度1.27(50℃)的清膏,加入步骤(1)所制细粉,混合均匀制粒,干燥,分筛,装入胶囊内,即得胶囊剂。
典型病例:xxx,女,59岁。主诉:患有糖尿病多年,2天前无明显诱因突然出现高热,体温39.4℃,伴发冷和寒战,同时还有剧烈头痛,频繁呕吐,食物和胆汁皆被吐出,上腹部没有不适症状,发病后,进食少,大小便正常,以为是一般的感冒发烧,于是服用退烧药和消炎药,后症状未见好转,遂到医院就诊。就诊时神志清楚,皮肤躯干有少量出血点,咽充血,其他各项指标均正常,经多项检查,确诊为流行性脑脊髓膜炎。
经人介绍得知本发明,服用本实施例所得治疗流行性脑脊髓膜炎的中药剂胶囊剂,每次2-4颗,每天3次,温开水冲服,15天一个疗程。服用5天后,患者呕吐恶心消失,食欲改善,头痛也缓解许多,遂继续服用,使用两个疗程后,患者所有不适症状消失,自感痊愈,1年后随访,未复发。
实施例3 治疗流行性脑脊髓膜炎的中药剂,主要由下列原料药制备而成:贯众7g,连翘9g,板蓝根10g,辣子草4g,赛金刚8g,长春花10g,木莲果7g,杏仁12g,黄芪16g,僵蚕3.5g,葶苈子6g,百合6g。
治疗流行性脑脊髓膜炎的中药剂稠膏剂的制备方法是:
(1)将赛金刚用清水浸润,切片,然后置于锅中炒至黑色为度,喷洒清水,放凉;
(2)取其他药材去杂质,洗净,与赛金刚一起置于砂锅中浸泡 60分钟,然后密闭大火煮20分钟,过滤,收集滤液,滤渣兑水(兑水量为刚好没过药材2cm)再次煎煮20分钟,过滤,合并两次滤液;
(3)将步骤(2)所得滤液加热浓缩至约200ml,加入面粉,不断搅拌,熬成稠膏状,即得稠膏剂。
典型病例:xxx,男,16岁。主诉:一周前开始头痛,伴有呕吐、皮肤瘀斑、烦躁。就诊时意识模糊,昏迷,体温不升高,口唇发绀,全身可见明显瘀点、瘀斑,经检查,脑膜刺激征为阳性,最终诊断为流行性脑脊髓膜炎。服用一些抗生素药,出现了副反应。
后打听得知本发明,服用本实施例所得治疗流行性脑脊髓膜炎的中药剂稠膏剂,采用每天三次,每次一汤勺,约6-8g,用温开水冲服,15天一个疗程。服用7天后,呕吐烦躁等症状消失,神志清楚,服用一个疗程后,身上瘀斑变淡,身体无不适反应,服用两个疗程后,患者个方面反应良好,痊愈。
实施例4 治疗流行性脑脊髓膜炎的中药剂,主要由下列原料药制备而成:贯众10g,连翘10g,板蓝根14g,辣子草7g,赛金刚13g,长春花14g,木莲果9g,杏仁16g,黄芪19g,僵蚕4.5g,葶苈子10g,百合8g。
治疗流行性脑脊髓膜炎的中药剂散剂的制备方法是:
(1)将连翘、板蓝根和木莲果去杂质粉碎,用药材质量4倍的80%的乙醇浸泡,渗漉,收集渗漉液,残渣备用;
(2)将赛金刚用清水浸润,切片,然后置于锅中炒至黑色为度,喷洒清水,放凉;
(3)将剩余药材去杂质,洗净,和步骤(2)所制得药材一起粗粉,然后置于砂锅中,浸泡75分钟,大火煮开,转小火煎65分钟,然后趁热过200目筛,收集滤液;
(4)将步骤(1)(3)所得渗漉液和滤液合并,混匀,真空浓缩至稠膏,再喷雾干燥,粉碎过筛340目筛,灭菌,分装,即得散剂。
典型病例:xxx,女,10岁。5天前,患者出现发热和呕吐等症状,发热温度达39.1℃,伴有惊厥。就诊时,口唇发绀,身体出现大小不一的出血点和瘀斑,体温38℃。检查确诊为流行性脑脊髓膜炎,后经医院常规治疗3天效果不佳,呕吐症状有加重趋势。
后经打听的得知本发明,抱着试试的态度,服用本实施例所得治疗流行性脑脊髓膜炎的中药剂散剂,采用每天三次,每次一袋,用温开水冲服,15天一个疗程。服用6天后,恶心呕吐症状消失,体温正常,服用至一个疗程后,身上斑点明显变小,变浅,巩固服用一个疗程后,患者无不适症状,各方面均恢复正常,痊愈。
实施例5 治疗流行性脑脊髓膜炎的中药剂,主要由下列原料药制备而成:贯众8.5g,连翘9.5g,板蓝根12g,辣子草5.5g,赛金刚10.5g,长春花12g,木莲果8g,杏仁14g,黄芪17.5g,僵蚕4g,葶苈子8g,百合7g。
治疗流行性脑脊髓膜炎的中药剂汤剂的制备方法是:
(1)将连翘、板蓝根和木莲果去杂质粉碎,用药材重量3倍的80%的乙醇浸泡,然后渗漉(渗漉所用80%乙醇量为药材重量的5.5.倍),收集渗漉液,残渣备用;
(2)将赛金刚用清水浸润,切片,然后置于锅中炒至黑色为度,喷洒清水,放凉;
(3)将剩余药材去杂质,洗净,和步骤(2)所制得药材一起粗粉,然后置于砂锅中,浸泡75分钟,大火煮开,转小火煎65分钟,然后趁热过200目筛,收集滤液;
(4)将步骤(1)(3)所得渗漉液和滤液合并,混匀,加热浓缩至原来体积的三分之一,灭菌,分装,即得汤剂。
试验例1 实施例5所得治疗流行性脑脊髓膜炎的中药剂汤剂的临床应用:2011年6月-2012年12月,在4所医院筛选324例患者,其中女性148例,男性176例,年龄最大的17岁,最小年龄8个月,平均年龄9.3岁,平均病程2-6个月。诊断标准:(1) 多在春夏及初秋发病,常有病毒感染史。(2) 有发热,头痛,呕吐,腹泻,意识障碍,甚或惊厥昏迷等症状。婴幼儿前囟饱满。(3) 脑膜刺激征阳性,有时可引出病理反射。(4) 脑脊液外观清亮或微浑,压力轻度增高,细胞数大多在10 ~ 500/mm3之间,淋巴细胞占多数。蛋白轻度增多,糖和氯化物正常。少数病例脑脊液无明显改变。有条件者可作病毒分离及血清学检查。(5) 脑电图:常出现弥漫性慢波。
将患者随机分为两组,实验组224例和对照组100例,两组在性别、年龄、病程、病情等方面无显著差异(P>0.05),具有可比性。实验组服用实施例5所得产品,每天服用两次(温热),每次60m1-80m1(视具体情况有所调整),15天一个疗程,对照组服用其它药品(磺胺嘧啶片、阿司匹林、甲硝唑胶囊等常规药品)。服药期间对两组患者进行连续观察,记录症状及变化。
疗效情况判定标准:治愈:临床症状全部消失,理化指标检查正常,观察三个月未见反复;有效:临床症状减轻,病情得到控制,理化指标检查改善或正常;无效:临床症状无明显好转或加重。
治疗结果:服用实施例5所得汤剂的实验组患者,症状全部消除,恢复正常的有142例(63.4%), 症状明显减轻的患者69例(30.8%),实验组总有效率为94.2%,对照组被治愈的有53例(53%),症状好转的有35例(35%),对照组的总有效率为88%,由此可知,实施例5所得产品对风湿性心脏病的治疗效果较其他三种常规药好。且治疗期间,实验组患者未出现任何不良反应,说明本发明安全,可放心服用。
本发明配方中选取的原药材,贯众、连翘、板蓝根清热解毒、凉血止血;辣子草、赛金刚消炎止痛;黄芪补气固表、利尿消肿;僵蚕祛风解痉、化痰散结;葶苈子泻肺降气、祛痰平喘;百合养阴润肺、清心安神,诸药共奏清热解毒、补气固表、化痰散结之功效,对流行性脑脊髓膜炎有理想的治疗效果。
应当指出的是,具体实施方式只是本发明比较有代表性的例子,显然本发明的技术方案不限于上述实施例,还可以有很多变形。本领域的普通技术人员,以本发明所明确公开的或根据文件的书面描述毫无异议的得到的,均应认为是本专利所要保护的范围。
Claims (10)
1.治疗流行性脑脊髓膜炎的中药制剂,其特征在于,主要由下列原料药制备而成,均为重量份:贯众0.5-1.2,连翘0.4-1.5,板蓝根0.8-1.6,辣子草0.3-0.8,赛金刚0.6-1.5,长春花0.8-1.6,木莲果0.6-1.0,杏仁1.0-1.8,黄芪1.5-2.0,僵蚕0.3-0.5,葶苈子0.4-1.2,百合0.4-1.0。
2.如权利要求1所述的治疗流行性脑脊髓膜炎的中药制剂,其特征在于,贯众0.7-1.0,连翘0.9-1.0,板蓝根1.0-1.4,辣子草0.4-0.7,赛金刚0.8-1.3,长春花1.0-1.4,木莲果0.7-0.9,杏仁1.2-1.6,黄芪1.6-1.9,僵蚕0.35-0.45,葶苈子0.6-1.0,百合0.6-0.8(优选的,贯众0.85,连翘0.95,板蓝根1.2,辣子草0.55,赛金刚1.05,长春花1.2,木莲果0.8,杏仁1.4,黄芪1.75,僵蚕0.4,葶苈子0.8,百合0.7)。
3.如权利要求1-2任一所述的治疗流行性脑脊髓膜炎的中药制剂,其特征在于,将其制成药学上可接受的汤剂,所述汤剂的制备方法是:
(1)将连翘、板蓝根和木莲果去杂质粉碎,用药材重量3倍的80%的乙醇浸泡,然后渗漉,收集渗漉液;
(2)将赛金刚用清水浸润,切片,然后置于锅中炒至黑色为度,喷洒清水,放凉;
(3)将剩余药材去杂质,洗净,和步骤(2)所制得药材一起粗粉,然后置于砂锅中,浸泡60-90分钟(优选的,浸泡70-80分钟,更加优选的,浸泡75分钟),大火煮开,转小火煎50-80分钟(优选的,转小火煎60-70分钟,更加优选的,转小火煎65分钟),然后趁热过200目筛,收集滤液;
(4)将步骤(1)(3)所得渗漉液和滤液合并,混匀,加热浓缩至原来体积的三分之一,灭菌,分装,即得汤剂。
4.如权利要求3所述的治疗流行性脑脊髓膜炎的中药制剂,其特征在于,步骤(1)渗漉所用80%乙醇量为药材重量的4-7倍(优选的,为药材重量的5-6倍,更加优选的,为药材重量的5.5倍)。
5.如权利要求1-2任一所述的治疗流行性脑脊髓膜炎的中药制剂,其特征在于,将其制成药学上可接受的胶囊剂,所述胶囊剂的制备方法是:
(1)将贯众、板蓝根、僵蚕和百合去杂质,洗净,干燥,粉碎过120-180目筛(优选的,粉碎过140-160目筛,更加优选的,粉碎过150目筛);
(2)将赛金刚用清水浸润,切片,然后置于锅中炒至黑色为度,喷洒清水,放凉;
(3)将剩余药材去杂质后,和步骤(2)所制药材一起浸泡于砂锅中40分钟,然后大火煮开后,转至小火煎30-60分钟(优选的,转至小火煎40-50分钟,更加优选的,转至小火煎45分钟),高速离心过滤,得滤液;
(4)将步骤(3)所得滤液,减压浓缩至相对密度1.24-1.30(优选的,1.27)(50℃)的清膏,加入步骤(1)所制细粉,混合均匀制粒,干燥,分筛,装入胶囊内,即得胶囊剂。
6.如权利要求5所述的治疗流行性脑脊髓膜炎的中药制剂,其特征在于,步骤(3)浸泡所用水刚好没过药材3cm。
7.如权利要求1-2任一所述的治疗流行性脑脊髓膜炎的中药制剂,其特征在于,将其制成药学上可接受的稠膏剂,所述稠膏剂的制备方法是:
(1)将赛金刚用清水浸润,切片,然后置于锅中炒至黑色为度,喷洒清水,放凉;
(2)取其他药材去杂质,洗净,与赛金刚一起置于砂锅中浸泡 60分钟,然后密闭大火煮20分钟,过滤,收集滤液,滤渣兑水再次煎煮20分钟,过滤,合并两次滤液;
(3)将步骤(2)所得滤液加热浓缩至约200ml,加入面粉,不断搅拌,熬成稠膏状,即得稠膏剂。
8.如权利要求7所述的治疗流行性脑脊髓膜炎的中药制剂,其特征在于,步骤(2)滤渣兑水量为刚好没过药材2cm。
9.如权利要求1-2任一所述的治疗流行性脑脊髓膜炎的中药制剂,其特征在于,将其制成药学上可接受的散剂,所述散剂的制备方法是:
(1)将连翘、板蓝根和木莲果去杂质粉碎,用药材质量4倍的80%的乙醇浸泡,渗漉,收集渗漉液,残渣备用;
(2)将赛金刚用清水浸润,切片,然后置于锅中炒至黑色为度,喷洒清水,放凉;
(3)将剩余药材去杂质,洗净,和步骤(2)所制得药材一起粗粉,然后置于砂锅中,浸泡60-90分钟(优选的,浸泡70-80分钟,更加优选的,浸泡75分钟),大火煮开,转小火煎50-80分钟(优选的,转小火煎60-70分钟,更加优选的,转小火煎65分钟),然后趁热过200目筛,收集滤液;
(4)将步骤(1)(3)所得渗漉液和滤液合并,混匀,真空浓缩至稠膏,再喷雾干燥,粉碎过筛,灭菌,分装,即得散剂。
10.如权利要求9所述的治疗流行性脑脊髓膜炎的中药制剂,其特征在于,步骤(4)粉碎过300-400目筛(优选的,粉碎过340目筛)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410653814.5A CN104306679A (zh) | 2014-11-18 | 2014-11-18 | 治疗流行性脑脊髓膜炎的中药剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410653814.5A CN104306679A (zh) | 2014-11-18 | 2014-11-18 | 治疗流行性脑脊髓膜炎的中药剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104306679A true CN104306679A (zh) | 2015-01-28 |
Family
ID=52362088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410653814.5A Pending CN104306679A (zh) | 2014-11-18 | 2014-11-18 | 治疗流行性脑脊髓膜炎的中药剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104306679A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104758737A (zh) * | 2015-01-31 | 2015-07-08 | 济南骄泰信息技术有限公司 | 一种治疗流行性脑脊髓膜炎的中药及其制备方法 |
CN106362014A (zh) * | 2016-08-31 | 2017-02-01 | 顾明明 | 一种治疗流行性脑脊髓膜炎的中西药复方制剂 |
CN111358846A (zh) * | 2020-05-14 | 2020-07-03 | 西安市胸科医院 | 一种具有改善中枢神经系统炎症的药剂 |
CN114767827A (zh) * | 2022-04-10 | 2022-07-22 | 西安市胸科医院(西安市结核病胸部肿瘤医院) | 一种具有改善中枢神经系统炎症的药剂 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63179812A (ja) * | 1987-01-22 | 1988-07-23 | Shiseido Co Ltd | 皮膚外用剤 |
CN102119994A (zh) * | 2010-01-12 | 2011-07-13 | 冯陆冰 | 一种治疗小儿外感发热的中药灌肠液 |
-
2014
- 2014-11-18 CN CN201410653814.5A patent/CN104306679A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63179812A (ja) * | 1987-01-22 | 1988-07-23 | Shiseido Co Ltd | 皮膚外用剤 |
CN102119994A (zh) * | 2010-01-12 | 2011-07-13 | 冯陆冰 | 一种治疗小儿外感发热的中药灌肠液 |
Non-Patent Citations (2)
Title |
---|
石四维: "《秀色养生:花卉药膳与便方》", 31 January 2005 * |
苗道仁等: "清热解毒口服液治疗发热性疾病300例", 《上海中医药杂志》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104758737A (zh) * | 2015-01-31 | 2015-07-08 | 济南骄泰信息技术有限公司 | 一种治疗流行性脑脊髓膜炎的中药及其制备方法 |
CN106362014A (zh) * | 2016-08-31 | 2017-02-01 | 顾明明 | 一种治疗流行性脑脊髓膜炎的中西药复方制剂 |
CN111358846A (zh) * | 2020-05-14 | 2020-07-03 | 西安市胸科医院 | 一种具有改善中枢神经系统炎症的药剂 |
CN114767827A (zh) * | 2022-04-10 | 2022-07-22 | 西安市胸科医院(西安市结核病胸部肿瘤医院) | 一种具有改善中枢神经系统炎症的药剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104306679A (zh) | 治疗流行性脑脊髓膜炎的中药剂及其制备方法 | |
CN102366465A (zh) | 一种三黄清解药物组合物及其制备方法 | |
CN104001045A (zh) | 一种用于治疗犬肺炎的药物及其制备方法 | |
CN104758900A (zh) | 一种用于治疗急性胰腺炎的中药 | |
CN103735710B (zh) | 用于治疗奶牛隐性乳房炎的中药组合物及其制备方法 | |
CN103041079B (zh) | 无糖型麻苏止咳复方制剂的制备方法 | |
CN105853901A (zh) | 癌症病人放化疗期间服用的制剂及制法 | |
CN112107673A (zh) | 一种治疗肺炎病的口服中药及其制备方法 | |
CN105535730A (zh) | 一种治疗咳嗽的新型中药组合物及其制备方法 | |
CN110624060A (zh) | 一种治疗幼儿腹泻的中药制剂及其制备方法 | |
CN104666475A (zh) | 一种治疗干燥综合症的黄连阿胶组合物及其应用 | |
CN103860942A (zh) | 用于治疗痰浊结聚型鼻咽癌的药物及其制备方法 | |
CN103735906A (zh) | 一种治疗干性支气管扩张的中药制剂及其制备方法 | |
CN103623232A (zh) | 一种治疗支气管炎的中药 | |
CN103623278B (zh) | 一种治疗冬令咳嗽的中药 | |
CN103100009B (zh) | 一种治疗乳管痹阻型急性乳腺炎的中药洗剂制备方法 | |
CN102920943B (zh) | 一种治疗腹膜后脓肿的中药 | |
CN106511812A (zh) | 一种治疗伤风感冒的药物及其制备方法 | |
CN104784567B (zh) | 一种治疗泌尿系感染的药物组合物 | |
CN112675282A (zh) | 一种治疗肺炎的组合物、制备方法及其制备的颗粒 | |
CN104721534A (zh) | 治疗急性咽炎的制剂及制备方法 | |
CN104740162A (zh) | 一种治疗肺炎链球菌性肺炎痰热壅肺证的药物与及其制备方法 | |
CN103933427A (zh) | 用于治疗结节性霉素疹的药物组合物及其制备方法 | |
CN105521026A (zh) | 一种治疗流行性脑脊髓膜炎的注射液 | |
CN104666811A (zh) | 一种胃蛋白酶处理的知柏地黄口服液的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: Beijing District of Gansu province Ludongming 730900 Baiyin District No. 4 1-502 Applicant after: Hao Jianyou Address before: Huaiyin District of Ji'nan City, Shandong province 250000 Ji Qi Road No. 112 Applicant before: Hao Jianyou |
|
COR | Change of bibliographic data | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150128 |